This publication discusses findings from two surveys conducted among end users and healthcare providers/policy makers to understand their perspectives on, and the facilitators and barriers to potential long-acting therapies for Hepatitis C virus (HCV) cure currently being developed by the LONGEVITY consortium, funded by the global health agency Unitaid.
This webinar will provide a platform to learn about the findings from the Longevity HCV and TB end users and healthcare providers/policy makers surveys, and for community members, especially marginalized populations across the world, to engage with the researchers developing these Long-Acting Therapies.
The nomination of Dr. Jay Bhattacharya for Director of the United States National Institutes of Health (NIH) continues the pattern of un- and under-qualified nominees put forward by the current administration.
Treatment Action Group (TAG) is disgusted and appalled by the new presidential administration’s flagrant attack on science.
People living with or at risk of hepatitis C Virus (HCV), health care providers, and policymakers in low- and middle-income countries (LMICs) showed significant interest in a potential long-acting HCV cure, recent surveys have found.
Treatment Action Group (TAG) is appalled by President Donald Trump’s executive order Monday signaling the United States will be withdrawing from the World Health Organization (WHO).
This year’s edition of TAGline takes stock of the state of the HIV, TB, and HCV pandemics worldwide, and advances bold visions for what a future without them must look like.
This World Hepatitis Day, July 28, we are better positioned than ever to end hepatitis C Virus (HCV) as a pandemic.
We're pleased to share with you our latest Annual Report, which highlights everything we accomplished in 2023.
TAG hosted this May 31 webinar on the growing pipeline of microarray patches (MAPs) for various infectious diseases treatment and immunization.